Viridian Therapeutics Inc

Research Viridian Therapeutics Inc (VRDN) on Bullrun: market cap USD 2.07B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVRDN
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 2.07B
• Financial periodFY2025
• RevenueUSD 70.85M
• Revenue growth23359.9%
• Net income-USD 342.60M
• Free cash flow-USD 276.89M

Valuation Snapshot

latest market cap is USD 2.07B.

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED.

Frequently asked questions

What is Viridian Therapeutics Inc's market cap?

Viridian Therapeutics Inc's market capitalization is USD 2.07B.

What does Viridian Therapeutics Inc do?

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.